Bioroundup: Stem-cell science and money, genetic tests go political, clinical-trial data woes, and more
(NOTE: Apologies — especially to RSS readers — if you’ve seen this post before, but an apparent server error ate it late yesterday and I was only able to recover it this morning. Enjoy, or ignore, as seems most fit.)
Featured stories:
Stem-cell science, money and death
Gene… Continue Reading
Life sciences briefing: Monday, Jan. 14, 2008
TODAY’S HEADLINES:
Autonomic Technologies raises $3M for neurostimulators (PE Hub)
Canopy Financial raises $15M for outsourced healthcare management (release)
Cancer-drug developer AmpliMed draws $5M (PE Hub)
Caprotec Bioanalytics receives €6M for protein-analysis tech (release)
ProtAffin draws additional €1.4M for anti-inflammatory drugs (release)
Toxicology-services firm Bridge Labs takes in $18M (release)
Dental-compound maker… Continue Reading
EnteroMedics and its risky obesity device, the latest victims of the IPO haircut
(UPDATED: See below.)
(NOTE: This item was originally published as part of today’s life-sciences briefing.)
EnteroMedics, a St. Paul, Minn., device maker working on a neuromodulation implant for treating obesity, slashed its expected IPO pricing by half, lowering it to a range of $8 to $9 instead of… Continue Reading
Life sciences briefing: Friday, Oct. 26, 2007
Featured companies: Allozyne, Arteriocyte Medical Systems, Arthrosurface, Bay City Capital, EnteroMedics, OncoVista, Novotech, Power Medical Interventions, Reliant Technologies
UPDATED: Expanded items on Allozyne, Reliant Tech, Power Medical and Bay City Capital.
UPDATE REDUX: Added item on EnteroMedics IPO.
Seattle’s Allozyne draws $30M for new interferon — Allozyne, a Seattle biotech… Continue Reading
Neuromodulator Innovative Metabolics picks up $5.5M
Innovative Metabolics, a Boston developer of neuromodulation systems for “chronic disease,” raised $5.5 million in a first funding round, VentureWire reports (subscription required). The round was led by Morgenthaler Ventures, which was joined by Foundation Medical Partners.
Although the company apparently still wants to keep a… Continue Reading
EnteroMedics plans $86M IPO for obesity-control implants
EnteroMedics, a St. Paul, Minn., developer of obesity-treatment implants, filed to raise up to $86.25 million in an IPO. Its S-1 filing with the SEC is here.
The company is developing a neuromodulation implant called VBLOC that is designed to intermittently disrupt signals sent along the… Continue Reading
Apnex Medical raises $16.1M for sleep-apnea devices
Apnex Medical, a Minneapolis maker of implants for the treatment of obstructive sleep apnea, raised $16.1 million in a first round of funding. Participants included Domain Associates, New Enterprise Associates, Polaris Ventures Partners and Apnex Chairman Michael Berman.
VentureWire reports that Apnex is using “neurostimulation” technology,… Continue Reading
NeuroVista raises $33.8M for epilepsy devices
(CORRECTED: See below.)
Seattle-based NeuroVista, a developer of devices for the treatment of epilepsy, raised $33.8 million in a second-round funding and left behind its former name, BioNeuronics.
The company, founded in 2002 by whiz kid Daniel DiLorenzo, has been quiet about its technology and commercial direction. In… Continue Reading
CVRx, developer of hypertension-treatment devices, draws in $65M
CVRx, a Minneapolis-based developer of an implantable device for the control of high blood pressure, raised $65 million in a fourth round of funding that will support a “pivotal” clinical trial of the device. The round was led by Johnson & Johnson Development, and also… Continue Reading